Latest news and press releases about Invivyd, Inc. (IVVD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease.
Price
| Price | $0.81 |
| Market Cap | $237M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -0.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -59.73% |
| Return on Invested Capital | -59.39% |
| Return on Assets | -49.04% |
| Gross Margin | 91.35% |
| Operating Margin | -192.81% |
| Net Margin | -183.90% |
Related companies: CCCC · CDXS · GNFT · IMDX · NTHI · OABI · OBIO
Explore sector: Healthcare · Biotechnology
More sections of IVVD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks